A randomized trial of <scp>L</scp>actobacillus plantarum <scp>CJLP</scp>133 for the treatment of atopic dermatitis

Han, Youngshin; Kim, Bongjoon; Ban, Jeongsook; Lee, Jeongok; Kim, Beom Joon; Choi, Byung Sun; Hwang, Sung Ho; Ahn, Kangmo; Kim, Jihyun

doi:10.1111/pai.12010

Cited by 116 publications

(112 citation statements)

References 31 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…A 16-week trial by Han and colleagues 304 conducted in South Korea compared twice-daily Lactobacillus plantarum CJLP133 for 12 weeks against placebo in 118 children aged 1-13 years with eczema according to the Hanifin and Rajkas 8 criteria. Disease severity measured by the SCORAD index was significantly lower in the probiotic group than in the placebo group after 14 weeks (20.4 vs. 25.6; p = 0.044).…”

Section: Lactobacillus Plantarum Cjlp133mentioning

confidence: 99%

See 1 more Smart Citation

Scoping systematic review of treatments for eczema

Nankervis

Kim

Delamere

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

BackgroundEczema is a very common chronic inflammatory skin condition.ObjectivesTo update the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) systematic review of treatments for atopic eczema, published in 2000, and to inform health-care professionals, commissioners and patients about key treatment developments and research gaps.Data sourcesElectronic databases including MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Skin Group Specialised Register, Latin American and Caribbean Health Sciences Literature (LILACS), Allied and Complementary Medicine Database (AMED) and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched from the end of 2000 to 31 August 2013. Retrieved articles were used to identify further randomised controlled trials (RCTs).Review methodsStudies were filtered according to inclusion criteria and agreed by consensus in cases of uncertainty. Abstracts were excluded and non-English-language papers were screened by international colleagues and data were extracted. Only RCTs of treatments for eczema were included, as other forms of evidence are associated with higher risks of bias. Inclusion criteria for studies included availability of data relevant to the therapeutic management of eczema; mention of randomisation; comparison of two or more treatments; and prospective data collection. Participants of all ages were included. Eczema diagnosis was determined by a clinician or according to published diagnostic criteria. The risk of bias was assessed using the Cochrane Collaboration risk-of-bias tool. We used a standardised approach to summarising the data and the assessment of risk of bias and we made a clear distinction between what the studies found and our own interpretation of study findings.ResultsOf 7198 references screened, 287 new trials were identified spanning 92 treatments. Trial reporting was generally poor (randomisation method: 2% high, 36% low, 62% unclear risk of bias; allocation concealment: 3% high, 15% low, 82% unclear risk of bias; blinding of the intervention: 15% high, 28% low, 57% unclear risk of bias). Only 22 (8%) trials were considered to be at low risk of bias for all three criteria. There was reasonable evidence of benefit for the topical medications tacrolimus, pimecrolimus and various corticosteroids (with tacrolimus superior to pimecrolimus and corticosteroids) for both treatment and flare prevention; oral ciclosporin; oral azathioprine; narrow band ultraviolet B (UVB) light; Atopiclair™ and education. There was reasonable evidence to suggest no clinically useful benefit for twice-daily compared with once-daily topical corticosteroids; corticosteroids containing antibiotics for non-infected eczema; probiotics; evening primrose and borage oil; ion-exchange water softeners; protease inhibitor SRD441 (Serentis Ltd); furfuryl palmitate in emollient; cipamfylline cream; andMycobacterium vaccaevaccine. Additional research evidence is needed for emollients, bath additives, antibacterials, specialist clothing and complementary and alternative therapies. There was no RCT evidence for topical corticosteroid dilution, impregnated bandages, soap avoidance, bathing frequency or allergy testing.LimitationsThe large scope of the review coupled with the heterogeneity of outcomes precluded formal meta-analyses. Our conclusions are still limited by a profusion of small, poorly reported studies.ConclusionsAlthough the evidence base of RCTs has increased considerably since the last NIHR HTA systematic review, the field is still severely hampered by poor design and reporting problems including failure to register trials and declare primary outcomes, small sample size, short follow-up duration and poor reporting of risk of bias. Key areas for further research identified by the review include the optimum use of emollients, bathing frequency, wash products, allergy testing and antiseptic treatments. Perhaps the greatest benefit identified is the use of twice weekly anti-inflammatory treatment to maintain disease remission. More studies need to be conducted in a primary care setting where most people with eczema are seen in the UK. Future studies need to use the same core set of outcomes that capture patient symptoms, clinical signs, quality of life and the chronic nature of the disease.FundingThe National Institute for Health Research Programme Grants for Applied Research programme.

show abstract

Section: Lactobacillus Plantarum Cjlp133mentioning

confidence: 99%

“…Sixteen [289][290][291][292][293][294][295][296][297][298][299][300][301][302][303][304] new trials were reported after 2000. Nearly all of the 16 trials reported compared a probiotic against an inactive placebo or occasionally against no treatment.…”

Section: Studiesmentioning

confidence: 99%

Scoping systematic review of treatments for eczema

Nankervis

Kim

Delamere

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

show abstract

“…At the same time, another group reported that a synbiotic combination of L. salivarius plus FOS is superior to the prebiotic alone for treating moderate to severe childhood AD [131]. While some studies with probiotics as a treatment for AD show a benefit [132], most studies are negative. No benefit was reported from supplementation with B. animalis subsp.…”

Section: Allergy and Atopic Dermatitismentioning

confidence: 97%

Probiotics

Vandenplas¹,

Huys²,

Daube³

2015

Textbook of Pediatric Gastroenterology, Hepatology and Nutrition

View full text Add to dashboard Cite

“…For the positive control (PC), we chose to administer CJLP133 which has been proved to be beneficial in the treatment of AD [22]. A total of 40 mice were randomly assigned to 5 groups with 8 mice per group: untreated Balb/c mice, AD control (0.1% w/v DNCB-treated NC/Nga mice), PC (DNCB-treated NC/Nga mice fed a dietary supplement of 66.6 mg/kg of birth weight [b.w.]…”

Section: Methodsmentioning

confidence: 99%

Costaria costata Extract Suppresses Development of Atopic Dermatitis in chloro-2,4-dinitrobenzene-treated NC/Nga Mice

Kim¹,

Lee²,

Kwon³

et al. 2018

Skin Pharmacol Physiol

View full text Add to dashboard Cite

We investigated the potential effects of Costaria costata (CC) on atopic dermatitis (AD) development in chloro-2,4-dinitrobenzene (DNCB)-treated NC/Nga mice. CC is a brown alga distributed across the seas of Korea, China, and Japan. A total of 40 mice were randomly assigned to 5 groups with 8 mice per group: untreated Balb/c mice, AD control (0.1% w/v DNCB-treated NC/Nga mice), positive control (i.e., DNCB-treated NC/Nga mice fed a dietary supplement of 66.6 mg/kg of body weight [b.w.] of CJLP133), DNCB-treated NC/Nga mice fed a dietary supplement of 100 mg/kg b.w. of CCE10 (CCE10 100), and DNCB-treated mice fed a dietary supplement of 300 mg/kg b.w. of CCE10 (CCE10 300) groups. The CCE10 100 and CCE10 300 treatment groups suppressed AD development including clinical and histopathological changes and a reduction in skin hydration induced by DNCB. In addition, Th2 cytokine production in primary splenocytes, serum IgE and histamine production, and mast cell infiltration into the skin were suppressed in the CCE10 300 mice compared to the CCE10 100 mice. Our finding demonstrated an inhibitory effect of CCE10 in AD development by means of improving the Th1/Th2 cytokine balance and anti-inflammatory effect in an in vivo model.

show abstract

A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis

Abstract: Our results suggest that supplementation with probiotic L. plantarum CJLP133 is beneficial in the treatment of pediatric AD.

Cited by 116 publications

References 31 publications

Scoping systematic review of treatments for eczema

Scoping systematic review of treatments for eczema

Probiotics

<b><i>Costaria costata</i></b> Extract Suppresses Development of Atopic Dermatitis in chloro-2,4-dinitrobenzene-treated NC/Nga Mice

Contact Info

Product

Resources

About